Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its market share to biosimilar competitors.
For six years straight, AbbVie’s Humira reigned as the world’s best-selling drug.
The anti-TNF antibody bowed only to Pfizer and BioNTech’s COVID-19 vaccine Comirnaty in 2021, and yet even in the throes of the pandemic—when anti-infectives saw a surge in demand—Humira stood its ground, staying in the top three earners of the year.
In 2024, however, it became clear that Humira is no longer the dominant market force that it once was. Mounting biosimilar and competitive pressure have sent Humira’s sales steadily downward. The drug is no longer AbbVie’s biggest moneymaker and the pharma appears to no longer be investing in its growth. As per its latest pipeline update document, posted in January, AbbVie has no active studies or applications for Humira.
Humira’s fall is emblematic of the typical life cycle of drugs. John Gagliano, senior director at BioPharmCatalyst, expects to see a similar pattern play out in the coming years, as the industry faces the strongest patent headwinds in more than a decade.
“The overall landscape [of top drugs] is anticipated to become more diverse as emerging therapies gradually replace aging blockbusters,” he told BioSpace in an email. Companies can implement what Gagliano calls “defensive strategies” such as novel formulations, patent extensions and combination regimens to prolong the exclusivity of their drugs and “sustain their positions” in the market—but that only serves to delay the inevitable.
“Many current top sellers face imminent loss of exclusivity (LOE), which will likely trigger rapid revenue declines,” Gagliano continued.
In addition to Humira, Eliquis and Opdivo are likely to “drop out of the top ranks as biosimilars and generics enter the market,” predicts Gagliano’s colleague Olivia Tidwell, content coordinator at BioPharmCatalyst. Meanwhile, she continued, potentially rising to take their place are promising assets in emerging modalities, such as radioligand therapies, CAR Ts and gene therapies, among others.
Here, BioSpace looks at the top 10 pharma products that brought in the biggest sales in 2024. The list is a mix of predictable and surprising. Novo Nordisk’s Ozempic, for instance, was pretty much a shoo-in for this list, while several drugs facing LOE concerns—and were therefore expected to suffer slower sales—managed to maintain their market dominance.
Continue at: https://www.biospace.com/business/10-best-selling-drugs-of-2024-rake-in-billions-amid-exclusivity-threats
The text above is owned by the site above referred.
Here is only a small part of the article, for more please follow the link
Also see:
Manostaxx – Industrial Management Consulting
